The Level of TGF-β in Sera of Patients with Primary Sjögren's Syndrome

Overview

Journal Reumatologia

Publisher Termedia

Specialty Rheumatology

Date 2020 Apr 1

PMID 32226163

Citations 4

Authors

Maria Maslinska

Agnieszka Paradowska-Gorycka

Malgorzata Manczak

Kinga Kostyra-Grabczak

Brygida Kwiatkowska

Affiliations

Soon will be listed here.

Abstract

Objectives: Tumor growth factor β (TGF-β) is a pleiotropic cytokine which controls autoimmune reactions, cell proliferation, and the organ accumulation of lymphocytes. This cytokine has a protective and anti-inflammatory effect in autoimmune processes, but also has a pro-fibrinous activity. Therefore, its importance in the development of systemic sclerosis has been proven. The role of TGF-β in Sjögren's syndrome is also a valid direction of research. The aim of the presented study is to evaluate the level of TGF-β in sera of primary Sjögren's syndrome patients and to investigate possible correlations with autoantibodies, cytokines, and cells in biopsy of minor salivary glands active in the pathogenesis of this syndrome.

Material And Methods: Thirty-three primary Sjögren's syndrome patients were included. Routine laboratory tests and immunological assessment (ANA, anti SS-A, anti SS-B antibodies, rheumatoid factor), ophthalmological assessment with ocular staining scoring, chest X-ray, and high-resolution computed tomography (if necessary) were performed. Serum concentrations of cytokines such as TGF-β, BAFF, APRIL, FLT-3L, LT-α, IL-21, and TNF-α were evaluated using standard ELISA assays. The histopathological evaluation (focus score) and the determination of CD3+, CD4+, CD19+, CD21+, CD35+ cells was performed.

Results: There was no significant correlation between TGF-β and other tested cytokines or autoantibodies, other than TNF-α. A negative correlation (ρ = -0.472) between TGF-β and TNF-α was found. There were no correlations between TGF-β and: results of ocular examinations, elements of histopathological variables, or lungs changes.

Conclusions: The authors state that: 1) the results may indicate that TGF-β influences the serum TNF-α activity in pSS patients, 2) our findings suggest that TGF-β may be the strongest inhibitor of TNF-α among cytokines involved in pSS pathogenesis, and 3) the results may explain the ineffectiveness of anti-TNF drugs in the treatment of pSS.

Citing Articles

Occurrence and role of Tph cells in various renal diseases.

Ren J, Ma K, Lu X, Peng H, Wang J, Nasser M Mol Med. 2024; 30(1):174.

PMID: 39390361 PMC: 11468416. DOI: 10.1186/s10020-024-00919-3.

The role of M1/M2 macrophage polarization in primary Sjogren's syndrome.

Chen X, Zhu L, Wu H Arthritis Res Ther. 2024; 26(1):101.

PMID: 38745331 PMC: 11092035. DOI: 10.1186/s13075-024-03340-7.

Cell type-specific transforming growth factor-β (TGF-β) signaling in the regulation of salivary gland fibrosis and regeneration.

Munoz Forti K, Weisman G, Jasmer K J Oral Biol Craniofac Res. 2024; 14(3):257-272.

PMID: 38559587 PMC: 10979288. DOI: 10.1016/j.jobcr.2024.03.005.

Sclerosing Sialadenitis Is Associated With Salivary Gland Hypofunction and a Unique Gene Expression Profile in Sjögren's Syndrome.

Yin H, Pranzatelli T, French B, Zhang N, Warner B, Chiorini J Front Immunol. 2021; 12:699722.

PMID: 34400910 PMC: 8363566. DOI: 10.3389/fimmu.2021.699722.

References

Monteleone G, Neurath M, Ardizzone S, Di Sabatino A, Fantini M, Castiglione F . Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015; 372(12):1104-13. DOI: 10.1056/NEJMoa1407250. View

Verrecchia F, Mauviel A . TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal. 2004; 16(8):873-80. DOI: 10.1016/j.cellsig.2004.02.007. View

Catalan-Serra I, Brenna O . Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother. 2018; 14(11):2597-2611. PMC: 6314405. DOI: 10.1080/21645515.2018.1461297. View

Varga J, Pasche B . Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009; 5(4):200-6. PMC: 3959159. DOI: 10.1038/nrrheum.2009.26. View

Sisto M, Lorusso L, Ingravallo G, Tamma R, Ribatti D, Lisi S . The TGF-1 Signaling Pathway as an Attractive Target in the Fibrosis Pathogenesis of Sjögren's Syndrome. Mediators Inflamm. 2019; 2018:1965935. PMC: 6287147. DOI: 10.1155/2018/1965935. View

Tatler A, Jenkins G . TGF-β activation and lung fibrosis. Proc Am Thorac Soc. 2012; 9(3):130-6. DOI: 10.1513/pats.201201-003AW. View

Szondy Z, Pallai A . Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications. Pharmacol Res. 2016; 115:124-132. DOI: 10.1016/j.phrs.2016.11.025. View

Saxena V, Lienesch D, Zhou M, Bommireddy R, Azhar M, Doetschman T . Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J Immunol. 2008; 180(3):1903-12. PMC: 2291535. DOI: 10.4049/jimmunol.180.3.1903. View

Hall B, Zheng C, Swaim W, Cho A, Nagineni C, Eckhaus M . Conditional overexpression of TGF-beta1 disrupts mouse salivary gland development and function. Lab Invest. 2010; 90(4):543-55. PMC: 2847636. DOI: 10.1038/labinvest.2010.5. View

10.

Loubaki L, Chabot D, Bazin R . Involvement of the TNF-α/TGF-β/IDO axis in IVIg-induced immune tolerance. Cytokine. 2014; 71(2):181-7. DOI: 10.1016/j.cyto.2014.10.016. View

11.

Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K . Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol. 2003; 171(7):3855-62. DOI: 10.4049/jimmunol.171.7.3855. View

12.

Kulkarni K, Selesniemi K, Brown T . Interferon-gamma sensitizes the human salivary gland cell line, HSG, to tumor necrosis factor-alpha induced activation of dual apoptotic pathways. Apoptosis. 2006; 11(12):2205-15. DOI: 10.1007/s10495-006-0281-8. View

13.

Konkel J, Zhang D, Zanvit P, Chia C, Zangarle-Murray T, Jin W . Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses. Immunity. 2017; 46(4):660-674. DOI: 10.1016/j.immuni.2017.03.015. View

14.

Moutsopoulos N, Katsifis G, Angelov N, Leakan R, Sankar V, Pillemer S . Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008; 67(10):1437-43. DOI: 10.1136/ard.2007.077891. View

15.

Fechtner S, Fox D, Ahmed S . Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2016; 56(7):1060-1068. PMC: 5850516. DOI: 10.1093/rheumatology/kew301. View

16.

Rice L, Padilla C, McLaughlin S, Mathes A, Ziemek J, Goummih S . Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015; 125(7):2795-807. PMC: 4563675. DOI: 10.1172/JCI77958. View

17.

Pallotta M, Orabona C, Volpi C, Vacca C, Belladonna M, Bianchi R . Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011; 12(9):870-8. DOI: 10.1038/ni.2077. View

18.

Zhou J, Kawai T, Yu Q . Pathogenic role of endogenous TNF-α in the development of Sjögren's-like sialadenitis and secretory dysfunction in non-obese diabetic mice. Lab Invest. 2017; 97(4):458-467. PMC: 5376226. DOI: 10.1038/labinvest.2016.141. View

19.

Verrecchia F, Pessah M, Atfi A, Mauviel A . Tumor necrosis factor-alpha inhibits transforming growth factor-beta /Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem. 2000; 275(39):30226-31. DOI: 10.1074/jbc.M005310200. View

20.

Shen L, Suresh L, Wu J, Xuan J, Li H, Zhang C . A role for lymphotoxin in primary Sjogren's disease. J Immunol. 2010; 185(10):6355-63. DOI: 10.4049/jimmunol.1001520. View